The hAPP-YAC transgenic model has elevated UPS activity in the frontal cortex similar to Alzheimer's disease and Down's syndrome

Journal of Neurochemistry

Volumn 114, Issue 6, 2010, Pages 1819-1826

  Seo, Hyemyung ^a,b   Isacson, Ole ^a  

^a MCLEAN HOSPITAL   (United States)

^b Hanyang University   (South Korea)

Author keywords

amyloid precursor protein; cortex; patient; proteasome; transgenic mice; ubiquitin

Indexed keywords

2 ETHYL 8 METHYL 2,8 DIAZASPIRO[4.5]DECANE 1,3 DIONE; ALPHA SECRETASE; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; CHYMOTRYPSIN; NERVE GROWTH FACTOR; PROTEASOME; UBIQUITIN; MUSCARINIC M1 RECEPTOR; SECRETASE;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHOLINERGIC STIMULATION; CONTROLLED STUDY; DOWN REGULATION; DOWN SYNDROME; FRONTAL CORTEX; GENE OVEREXPRESSION; HIPPOCAMPUS; HUMAN; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN SECRETION; TRANSGENIC MOUSE; UPREGULATION; YEAST ARTIFICIAL CHROMOSOME; AGONISTS; ANIMAL; BIOSYNTHESIS; FRONTAL LOBE; GENETICS; METABOLISM;

MUS; MUS MUSCULUS;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; CHROMOSOMES, ARTIFICIAL, YEAST; DOWN SYNDROME; FRONTAL LOBE; HUMANS; MICE; MICE, TRANSGENIC; NERVE GROWTH FACTOR; PROTEASOME ENDOPEPTIDASE COMPLEX; RECEPTOR, MUSCARINIC M1; UBIQUITIN; UP-REGULATION;

EID: 77956329435     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2010.06902.x     Document Type: Article

References (38)

1. Cattaneo A., Capsoni S. Paoletti F. (2008) Towards non invasive nerve growth factor therapies for Alzheimer's disease. J. Alzheimer's Dis. 15, 255 283.
2. Cecarini V., Bonfili L., Amici M., Angeletti M., Keller J. N. Eleuteri A. M. (2008) Amyloid peptides in different assembly states and related effects on isolated and cellular proteasomes. Brain Res. 1209, 8 18.
3. Craiu A., Gaczynska M., Akopian T., Gramm C. F., Fenteany G., Goldberg A. L. Rock K. L. (1997) Lactacystin and clasto-lactacystin beta-lactone modify multiple proteasome beta-subunits and inhibit intracellular protein degradation and major histocompatibility complex class I antigen presentation. J. Biol. Chem. 272, 13437 13445.
4. Fisher L. J., Raymon H. K. Gage F. H. (1993) Cells engineered to produce acetylcholine: therapeutic potential for Alzheimer's disease. Ann. NY Acad. Sci. 695, 278 284.
5. Fisher A., Heldman E., Gurwitz D. et al. (1996) M1 agonists for the treatment of Alzheimer's disease. Novel properties and clinical update. Ann. NY Acad. Sci. 777, 189 196.
6. Fraser P. E., Levesque G., Yu G. et al. (1998) Presenilin 1 is actively degraded by the 26S proteasome. Neurobiol. Aging 19, S19 S21.
7. Gregori L., Fuchs C., Figueiredo-Pereira M. E., Van Nostrand W. E. Goldgaber D. (1995) Amyloid beta-protein inhibits ubiquitin-dependent protein degradation in vitro. J. Biol. Chem. 270, 19702 19708.
8. Haass C., Grunberg J., Capell A. et al. (1998) Proteolytic processing of Alzheimer's disease associated proteins. J. Neural Transm. Suppl. 53, 159 167.
9. Harman D. (2006) Alzheimer's disease pathogenesis: role of aging. Ann. NY Acad. Sci. 1067, 454 460.
10. Honda T., Yasutake K., Nihonmatsu N. et al. (1999) Dual roles of proteasome in the metabolism of presenilin 1. J. Neurochem. 72, 255 261.
11. Isacson O., Seo H., Lin L., Albeck D. Granholm A. C. (2002) Alzheimer's disease and Down's syndrome: roles of APP, trophic factors and ACh. Trends Neurosci. 25, 79 84.
12. Keck S., Nitsch R., Grune T. Ullrich O. (2003) Proteasome inhibition by paired helical filament-tau in brains of patients with Alzheimer's disease. J. Neurochem. 85, 115 122.
13. Keller J. N., Hanni K. B. Markesbery W. R. (2000) Impaired proteasome function in Alzheimer's disease. J. Neurochem. 75, 436 439.
14. Kimura R. Ohno M. (2009) Impairments in remote memory stabilization precede hippocampal synaptic and cognitive failures in 5XFAD Alzheimer mouse model. Neurobiol. Dis. 33, 229 235.
15. Lamb B. T. (1995) Making models for Alzheimer's disease. Nat. Genet. 9, 4 6.
16. Lamb B. T., Sisodia S. S., Lawler A. M., Slunt H. H., Kitt C. A., Kearns W. G., Pearson P. L., Price D. L. Gearhart J. D. (1993) Introduction and expression of the 400 kilobase amyloid precursor protein gene in transgenic mice [corrected]. Nat. Genet. 5, 22 30.
17. Lamb B. T., Call L. M., Slunt H. H. et al. (1997) Altered metabolism of familial Alzheimer's disease-linked amyloid precursor protein variants in yeast artificial chromosome transgenic mice. Hum. Mol. Genet. 6, 1535 1541.
18. Marambaud P., Zhao H. Davies P. (2005) Resveratrol promotes clearance of Alzheimer's disease amyloid-beta peptides. J. Biol. Chem. 280, 37377 37382.
19. Mufson E. J., Counts S. E., Perez S. E. Ginsberg S. D. (2008) Cholinergic system during the progression of Alzheimer's disease: therapeutic implications. Expert. Rev. Neurother. 8, 1703 1718.
20. Neve R. L., McPhie D. L. Chen Y. (2000) Alzheimer's disease: a dysfunction of the amyloid precursor protein(1). Brain Res. 886, 54 66.
21. Nunan J., Shearman M. S., Checler F., Cappai R., Evin G., Beyreuther K., Masters C. L. Small D. H. (2001) The C-terminal fragment of the Alzheimer's disease amyloid protein precursor is degraded by a proteasome-dependent mechanism distinct from gamma-secretase. Eur. J. Biochem. 268, 5329 5336.
22. Palacios J. M., Bolliger G., Closse A., Enz A., Gmelin G. Malanowski J. (1986) The pharmacological assessment of RS 86 (2-ethyl-8-methyl-2,8-diazaspiro- [4,5]-decan-1,3-dion hydrobromide). A potent, specific muscarinic acetylcholine receptor agonist. Eur. J. Pharmacol. 125, 45 62.
23. Pan T., Kondo S., Le W. Jankovic J. (2008) The role of autophagy-lysosome pathway in neurodegeneration associated with Parkinson's disease. Brain 131, 1969 1978.
24. Rossner S., Ueberham U., Schliebs R., Perez-Polo J. R. Bigl V. (1998) The regulation of amyloid precursor protein metabolism by cholinergic mechanisms and neurotrophin receptor signaling. Prog. Neurobiol. 56, 541 569.
25. Rupniak N. M., Tye S. J. Iversen S. D. (1992) Comparison of the effects of selective and nonselective muscarinic agonists on cognition and thermoregulation in primates. J. Neurol. Sci. 110, 222 227.
26. Sarsoza F., Saing T., Kayed R. et al. (2009) A fibril-specific, conformation-dependent antibody recognizes a subset of Abeta plaques in Alzheimer disease, Down syndrome and Tg2576 transgenic mouse brain. Acta Neuropathol. 118, 505 517.
27. Seo H. Isacson O. (2005) Abnormal APP, cholinergic and cognitive function in Ts65Dn Down's model mice. Exp. Neurol. 193, 469 480.
28. Seo H., Ferree A. W. Isacson O. (2002) Cortico-hippocampal APP and NGF levels are dynamically altered by cholinergic muscarinic antagonist or M1 agonist treatment in normal mice. Eur. J. Neurosci. 15, 498 506.
29. Seo H., Sonntag K. C. Isacson O. (2004) Generalized brain and skin proteasome inhibition in Huntington's disease. Ann. Neurol. 56, 319 328.
30. Seo H., Kim W. Isacson O. (2008) Compensatory changes in the ubiquitin-proteasome system, brain-derived neurotrophic factor and mitochondrial complex II/III in YAC72 and R6/2 transgenic mice partially model Huntington's disease patients. Hum. Mol. Genet. 17, 3144 3153.
31. Steiner H., Capell A., Pesold B., Citron M., Kloetzel P. M., Selkoe D. J., Romig H., Mendla K. Haass C. (1998) Expression of Alzheimer's disease-associated presenilin-1 is controlled by proteolytic degradation and complex formation. J. Biol. Chem. 273, 32322 32331.
32. Suzuki N., Cheung T. T., Cai X. D., Odaka A., Otvos Jr. L., Eckman C., Golde T. E. Younkin S. G. (1994) An increased percentage of long amyloid beta protein secreted by familial amyloid beta protein precursor (beta APP717) mutants. Science 264, 1336 1340.
33. Teller J. K., Russo C., DeBusk L. M. et al. (1996) Presence of soluble amyloid beta-peptide precedes amyloid plaque formation in Down's syndrome. Nat. Med. 2, 93 95.
34. Upadhya S. C. Hegde A. N. (2007) Role of the ubiquitin proteasome system in Alzheimer's disease. BMC Biochem. 8 (Suppl. 1 S12.
35. Wanibuchi F., Konishi T., Harada M., Terai M., Hidaka K., Tamura T., Tsukamoto S. Usuda S. (1990) Pharmacological studies on novel muscarinic agonists, 1-oxa-8-azaspiro[4.5]decane derivatives, YM796 and YM954. Eur. J. Pharmacol. 187, 479 486.
36. Yamazaki T. Ihara Y. (1998) Effects of specific protease inhibitors on amyloid beta-protein 42 secretion. Neurobiol. Aging 19, S77 S79.
37. Zettler C., Bridges D. C., Zhou X. F. Rush R. A. (1996) Detection of increased tissue concentrations of nerve growth factor with an improved extraction procedure. J. Neurosci. Res. 46, 581 594.
38. Zuchner T., Perez-Polo J. R. Schliebs R. (2004) Beta-secretase BACE1 is differentially controlled through muscarinic acetylcholine receptor signaling. J. Neurosci. Res. 77, 250 257.